Dicerna Stock Analysis

DRNA -  USA Stock  

USD 35.84  0.30  0.84%

The current price rise of Dicerna Pharmaceutic could raise concerns from investors as the firm it trading at a share price of 35.84 on 230,149 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.62. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Dicerna Pharmaceutic partners.
Continue to Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Dicerna Pharmaceutic stock analysis report makes it easy to digest most publicly released information about Dicerna Pharmaceutic and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Dicerna stock analysis module also helps to analyze the Dicerna Pharmaceutic price relationship with some important fundamental indicators such as market cap and management efficiency.

Dicerna Stock Analysis Notes

About 84.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.52. Dicerna Pharmaceutic had not issued any dividends in recent years. Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference -based pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. Dicerna Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people. To learn more about Dicerna Pharmaceutic call Douglas Fambrough at 617 621-8097 or check out www.dicerna.com.

Dicerna Pharmaceutic Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Dicerna Pharmaceutic's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Dicerna Pharmaceutic or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Dicerna Pharmaceutic appears to be risky and price may revert if volatility continues
Dicerna Pharmaceutic is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 164.31 M. Net Loss for the year was (112.75 M) with loss before overhead, payroll, taxes, and interest of (41.08 M).
Dicerna Pharmaceutic has a poor financial position based on the latest SEC disclosures
Over 84.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.equities.com: Dicerna Pharmaceuticals Inc gains 1.8200 percent for June 14 - Equities.com

Dicerna Pharmaceutic Upcoming and Recent Events

Earnings reports are used by Dicerna Pharmaceutic to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dicerna Pharmaceutic previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Dicerna Largest EPS Surprises

Earnings surprises can significantly impact Dicerna Pharmaceutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-08-08
2019-06-30-0.3101-0.35-0.039912 
2020-11-05
2020-09-30-0.2428-0.29-0.047219 
2015-08-06
2015-06-30-0.78-0.86-0.0810 
View All Earnings Estimates

Dicerna Pharmaceutic SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Dicerna Pharmaceutic prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Dicerna Pharmaceutic investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Dicerna Pharmaceutic specific information freely available to individual and institutional investors to make a timely investment decision.
4th of June 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
View
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of April 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
12th of March 2021
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
View
2nd of March 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
25th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of February 2021
Unclassified Corporate Event
View
4th of February 2021
Unclassified Corporate Event
View

Dicerna Pharmaceutic Thematic Classifications

In addition to having Dicerna Pharmaceutic stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Dicerna Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.86 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dicerna Pharmaceutic's market, we take the total number of its shares issued and multiply it by Dicerna Pharmaceutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Dicerna Profitablity

Dicerna Pharmaceutic's profitability indicators refer to fundamental financial ratios that showcase Dicerna Pharmaceutic's ability to generate income relative to its revenue or operating costs. If, let's say, Dicerna Pharmaceutic is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Dicerna Pharmaceutic's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Dicerna Pharmaceutic's profitability requires more research than a typical breakdown of Dicerna Pharmaceutic's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (68.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (68.9) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.69.
Last ReportedProjected for 2021
Return on Investment(78.09) (84.25) 
Return on Average Assets(0.15) (0.17) 
Return on Average Equity(0.71) (0.77) 
Return on Invested Capital(0.34) (0.37) 
Return on Sales(0.69) (0.74) 

Management Efficiency

The entity has return on total asset (ROA) of (10.84) % which means that it has lost $10.84 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (77.77) %, meaning that it created substantial loss on money invested by shareholders. Dicerna Pharmaceutic management efficiency ratios could be used to measure how well dicerna pharmaceutic manages its routine affairs as well as how well it operates its assets and liabilities. As of June 17, 2021, Return on Investment is expected to decline to -84.25. In addition to that, Return on Average Assets is expected to decline to -0.17. Dicerna Pharmaceutic Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 707.85 Million. The current year Current Assets is expected to grow to about 667.5 M, whereas Tax Assets are forecasted to decline to about 1.4 M.
Last ReportedProjected for 2021
Book Value per Share 1.86  2.00 
Enterprise Value over EBIT(13.00) (13.34) 
Enterprise Value over EBITDA(13.31) (13.66) 
Price to Book Value 12.00  12.95 
Tangible Assets Book Value per Share 9.54  9.79 
Enterprise Value1.5 B1.6 B
Tangible Asset Value707.8 M763.7 M

Technical Drivers

As of the 17th of June 2021, Dicerna Pharmaceutic shows the Semi Deviation of 3.56, downside deviation of 3.98, and Mean Deviation of 2.83. Dicerna Pharmaceutic technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Dicerna Pharmaceutic, which can be compared to its rivals. Please confirm Dicerna Pharmaceutic downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Dicerna Pharmaceutic is priced favorably, providing market reflects its regular price of 35.84 per share. Given that Dicerna Pharmaceutic has jensen alpha of 0.4129, we urge you to verify Dicerna Pharmaceutic's prevailing market performance to make sure the company can sustain itself at a future point.

Dicerna Pharmaceutic Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Dicerna Pharmaceutic more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Dicerna Pharmaceutic Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dicerna Pharmaceutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dicerna Pharmaceutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dicerna Pharmaceutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Martin Freed over a week ago via Macroaxis 
Acquisition by Martin Freed of 15000 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Regina Paglia over a week ago via Macroaxis 
Exercise or conversion by Regina Paglia of 4431 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Regina Paglia over a month ago via Macroaxis 
Exercise or conversion by Regina Paglia of 4431 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Bob Brown over a month ago via Macroaxis 
Exercise or conversion by Bob Brown of 10000 shares of Dicerna Pharmaceutic subject to Rule 16b-3
James Weissman over a month ago via Macroaxis 
Sale by James Weissman of 4904 shares of Dicerna Pharmaceutic
Regina Paglia over two months ago via Macroaxis 
Exercise or conversion by Regina Paglia of 4431 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Regina Paglia over three months ago via Macroaxis 
Exercise or conversion by Regina Paglia of 4431 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Stephen Hoffman over three months ago via Macroaxis 
Acquisition or disposition of Dicerna Pharmaceutic securities by Stephen Hoffman
Pagan Douglas W over three months ago via Macroaxis 
Acquisition by Pagan Douglas W of 36900 shares of Dicerna Pharmaceuticals subject to Rule 16b-3
James Weissman over three months ago via Macroaxis 
Sale by James Weissman of 7156 shares of Dicerna Pharmaceutic
Regina Paglia over three months ago via Macroaxis 
Exercise or conversion by Regina Paglia of 4431 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Regina Paglia over three months ago via Macroaxis 
Exercise or conversion by Regina Paglia of 4431 shares of Dicerna Pharmaceuticals subject to Rule 16b-3

Dicerna Pharmaceutic Predictive Daily Indicators

Dicerna Pharmaceutic intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dicerna Pharmaceutic stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Dicerna Pharmaceutic Forecast Models

Dicerna Pharmaceutic time-series forecasting models is one of many Dicerna Pharmaceutic's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dicerna Pharmaceutic's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Dicerna Pharmaceutic Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dicerna Pharmaceutic stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dicerna shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Dicerna Pharmaceutic. By using and applying Dicerna Stock analysis, traders can create a robust methodology for identifying Dicerna entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(62.01) (66.91) 
EBITDA Margin(0.67) (0.73) 
Gross Margin 0.90  0.89 
Profit Margin(0.69) (0.74) 
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference -based pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. Dicerna Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people.

Current Dicerna Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dicerna analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dicerna analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
41.67Strong Buy6Odds
Dicerna Pharmaceutic current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Dicerna analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dicerna stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dicerna Pharmaceutic, talking to its executives and customers, or listening to Dicerna conference calls.
Dicerna Analyst Advice Details

Dicerna Stock Analysis Indicators

Dicerna Pharmaceutic stock analysis indicators help investors evaluate how Dicerna Pharmaceutic stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dicerna Pharmaceutic shares will generate the highest return on investment. By understating and applying Dicerna Pharmaceutic stock analysis, traders can identify Dicerna Pharmaceutic position entry and exit signals to maximize returns.
Quick Ratio3.40
Fifty Two Week Low16.50
Revenue Growth478.50%
Shares Short Prior Month5.16M
Average Daily Volume Last 10 Day573.53k
Average Daily Volume In Three Month725.41k
Shares Percent Shares Out7.27%
Gross Margins-25.00%
Short Percent Of Float7.59%
Forward Price Earnings-22.64
Float Shares63.56M
Fifty Two Week High37.44
Enterprise Value To Ebitda-16.17
Fifty Day Average29.71
Two Hundred Day Average26.47
Enterprise Value To Revenue10.93
Continue to Investing Opportunities. Note that the Dicerna Pharmaceutic information on this page should be used as a complementary analysis to other Dicerna Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Dicerna Pharmaceutic Stock analysis

When running Dicerna Pharmaceutic stock analysis, check to measure Dicerna Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dicerna Pharmaceutic is operating at the current time. Most of Dicerna Pharmaceutic's stock examination focuses on studying past and present price action to predict the probability of Dicerna Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dicerna Pharmaceutic's price. Additionally, you may evaluate how the addition of Dicerna Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
The market value of Dicerna Pharmaceutic is measured differently than its book value, which is the value of Dicerna that is recorded on the company's balance sheet. Investors also form their own opinion of Dicerna Pharmaceutic stock's value that differs from its market value or its book value, called intrinsic value, which is Dicerna Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dicerna Pharmaceutic's market value can be influenced by many factors that don't directly affect Dicerna Pharmaceutic underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dicerna Pharmaceutic's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Dicerna Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dicerna Pharmaceutic's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.